216 related articles for article (PubMed ID: 28819285)
21. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease.
Thomas EK; Cancelas JA; Chae HD; Cox AD; Keller PJ; Perrotti D; Neviani P; Druker BJ; Setchell KD; Zheng Y; Harris CE; Williams DA
Cancer Cell; 2007 Nov; 12(5):467-78. PubMed ID: 17996650
[TBL] [Abstract][Full Text] [Related]
22. Leukemogenesis of b2a2-type p210 BCR/ABL in a bone marrow transplantation mouse model using a lentiviral vector.
Uchida N; Hanawa H; Dan K; Inokuchi K; Shimada T
J Nippon Med Sch; 2009 Jun; 76(3):134-47. PubMed ID: 19602820
[TBL] [Abstract][Full Text] [Related]
23. BCR and its mutants, the reciprocal t(9;22)-associated ABL/BCR fusion proteins, differentially regulate the cytoskeleton and cell motility.
Zheng X; Güller S; Beissert T; Puccetti E; Ruthardt M
BMC Cancer; 2006 Nov; 6():262. PubMed ID: 17090304
[TBL] [Abstract][Full Text] [Related]
24. Unique dependence on Sos1 in
You X; Kong G; Ranheim EA; Yang D; Zhou Y; Zhang J
Blood; 2018 Dec; 132(24):2575-2579. PubMed ID: 30377195
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms through which Sos-1 coordinates the activation of Ras and Rac.
Innocenti M; Tenca P; Frittoli E; Faretta M; Tocchetti A; Di Fiore PP; Scita G
J Cell Biol; 2002 Jan; 156(1):125-36. PubMed ID: 11777939
[TBL] [Abstract][Full Text] [Related]
26. Abi1 gene silencing by short hairpin RNA impairs Bcr-Abl-induced cell adhesion and migration in vitro and leukemogenesis in vivo.
Yu W; Sun X; Clough N; Cobos E; Tao Y; Dai Z
Carcinogenesis; 2008 Sep; 29(9):1717-24. PubMed ID: 18453543
[TBL] [Abstract][Full Text] [Related]
27. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.
Skorski T; Bellacosa A; Nieborowska-Skorska M; Majewski M; Martinez R; Choi JK; Trotta R; Wlodarski P; Perrotti D; Chan TO; Wasik MA; Tsichlis PN; Calabretta B
EMBO J; 1997 Oct; 16(20):6151-61. PubMed ID: 9321394
[TBL] [Abstract][Full Text] [Related]
28. Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells.
Sattler M; Pride YB; Quinnan LR; Verma S; Malouf NA; Husson H; Salgia R; Lipkowitz S; Griffin JD
Oncogene; 2002 Feb; 21(9):1423-33. PubMed ID: 11857085
[TBL] [Abstract][Full Text] [Related]
29. Molecular biology of chronic myeloid leukemia.
Maru Y
Int J Hematol; 2001 Apr; 73(3):308-22. PubMed ID: 11345196
[TBL] [Abstract][Full Text] [Related]
30. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.
Cortez D; Kadlec L; Pendergast AM
Mol Cell Biol; 1995 Oct; 15(10):5531-41. PubMed ID: 7565705
[TBL] [Abstract][Full Text] [Related]
31. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
[TBL] [Abstract][Full Text] [Related]
32. PPDPF Promotes the Development of Mutant KRAS-Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1.
Ni QZ; Zhu B; Ji Y; Zheng QW; Liang X; Ma N; Jiang H; Zhang FK; Shang YR; Wang YK; Xu S; Zhang EB; Yuan YM; Chen TW; Yin FF; Cao HJ; Huang JY; Xia J; Ding XF; Qiu XS; Ding K; Song C; Zhou WT; Wu M; Wang K; Lui R; Lin Q; Chen W; Li ZG; Cheng SQ; Wang XF; Xie D; Li JJ
Adv Sci (Weinh); 2023 Jan; 10(2):e2202448. PubMed ID: 36453576
[TBL] [Abstract][Full Text] [Related]
33. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
[TBL] [Abstract][Full Text] [Related]
34. CRKL binding to BCR-ABL and BCR-ABL transformation.
Kolibaba KS; Bhat A; Heaney C; Oda T; Druker BJ
Leuk Lymphoma; 1999 Mar; 33(1-2):119-26. PubMed ID: 10194128
[TBL] [Abstract][Full Text] [Related]
35. FAK silencing inhibits leukemogenesis in BCR/ABL-transformed hematopoietic cells.
Le Y; Xu L; Lu J; Fang J; Nardi V; Chai L; Silberstein LE
Am J Hematol; 2009 May; 84(5):273-8. PubMed ID: 19358301
[TBL] [Abstract][Full Text] [Related]
36. p38 MAPK-mediated activation of NF-kappaB by the RhoGEF domain of Bcr.
Korus M; Mahon GM; Cheng L; Whitehead IP
Oncogene; 2002 Jul; 21(30):4601-12. PubMed ID: 12096337
[TBL] [Abstract][Full Text] [Related]
37. Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases.
Huang N; Huang Z; Gao M; Luo Z; Zhou F; Liu L; Xiao Q; Wang X; Feng W
J Exp Clin Cancer Res; 2018 Mar; 37(1):62. PubMed ID: 29554925
[TBL] [Abstract][Full Text] [Related]
38. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis.
Eiring AM; Neviani P; Santhanam R; Oaks JJ; Chang JS; Notari M; Willis W; Gambacorti-Passerini C; Volinia S; Marcucci G; Caligiuri MA; Leone GW; Perrotti D
Blood; 2008 Jan; 111(2):816-28. PubMed ID: 17925491
[TBL] [Abstract][Full Text] [Related]
39. PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.
Motiwala T; Majumder S; Ghoshal K; Kutay H; Datta J; Roy S; Lucas DM; Jacob ST
J Biol Chem; 2009 Jan; 284(1):455-464. PubMed ID: 18997174
[TBL] [Abstract][Full Text] [Related]
40. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.
Coluccia AM; Vacca A; Duñach M; Mologni L; Redaelli S; Bustos VH; Benati D; Pinna LA; Gambacorti-Passerini C
EMBO J; 2007 Mar; 26(5):1456-66. PubMed ID: 17318191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]